Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Lapatinib
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Breast Cancer
Fabricant:
GlaxoSmithKline
Brand Name:
Tykerb (in combination with Letrozole)
Gamme de produits:
Examen en vue du remboursement
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
250 mg
Tumour Type:
Breast
Indications:
Metastatic Breast Cancer
Funding Request:
In combination with letrozole for the treatment of postmenopausal patients with hormone receptor positive metastatic breast cancer, whose tumours overexpress the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy
Review Status:
Complete
Date NOC Issued:
Sponsor:
GlaxoSmithKline
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Ne pas rembourser
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016